Adjustment of the SMART risk score by bioactive adrenomedullin enables a more accurate prediction of mortality in patients with ASCVD.

BACKGROUND AND AIMS: Bioactive adrenomedullin 1-52 (bio-ADM) is a novel biomarker for the assessment of endothelial function and prediction of adverse outcomes in patients with acute heart failure and cardiogenic shock. The SMART (Second Manifestations of Arterial Disease) risk score is a validated tool for risk assessment in patients with established atherosclerotic cardiovascular disease (ASCVD). Here we assessed whether bio-ADM adds incremental prognostic value to the SMART risk score in stable patients with ASCVD.

METHODS

Circulating bio-ADM levels were measured in 452 stable patients with ASCVD. Endpoints evaluated were all-cause and cardiovascular mortality; follow up was 3 years.

RESULTS

Bio-ADM was higher in non-survivors (n = 45; median 36.8 pg/mL) compared to survivors (n = 407; median 18.3 pg/mL; p < 0.0001). Bio-ADM was found to be a strong predictor for all-cause mortality (Chi2: 44.58; C-index: 0.79) as well as cardiovascular death (Chi2: 33.29; C-index: 0.85) and proved to be superior to other markers including hs-Troponin T (Chi2: 7.77; C-index: 0.73) and eGFRCKD-EPI 2021 (Chi2: 25.10; C-index: 0.70). In multivariable analyses adjusting for age, sex, diabetes mellitus, hypertension, smoking, NT-proBNP, and eGFRCKD-EPI 2021, bio-ADM remained independently associated with all-cause mortality (HR: 1.6; 95 % CI: 1.2-2.1; Chi2: 96.17; p < 0.00001; C-index: 0.89) and cardiovascular death (HR: 1.7; 95 % CI: 1.1-2.5; Chi2: 57.71; p < 0.00001; C-index: 0.88). Addition of bio-ADM to the SMART risk score meaningfully improved model performance in predicting mortality (SMART risk score: Chi2: 19.91; p = 0.0001; C-index: 0.69; SMART risk score + bio-ADM: Chi2: 54.51; p < 0.00001; C-index: 0.81).

CONCLUSIONS

Bio-ADM levels are independently associated with mortality and provide incremental added value on top of the SMART risk score in stable patients with ASCVD.